| Literature DB >> 34500664 |
Muhammad Sulaiman Zubair1, Saipul Maulana1, Agustinus Widodo1, Ramadanil Pitopang2, Muhammad Arba3, Maywan Hariono4.
Abstract
This study aims to identify and isolate the secondary metabolites of Zingiber officinale using GC-MS, preparative TLC, and LC-MS/MS methods, to evaluate the inhibitory potency on SARS-CoV-2 3 chymotrypsin-like protease enzyme, as well as to study the molecular interaction and stability by using docking and molecular dynamics simulations. GC-MS analysis suggested for the isolation of terpenoids compounds as major compounds on methanol extract of pseudostems and rhizomes. Isolation and LC-MS/MS analysis identified 5-hydro-7, 8, 2'-trimethoxyflavanone (9), (E)-hexadecyl-ferulate (1), isocyperol (2), N-isobutyl-(2E,4E)-octadecadienamide (3), and nootkatone (4) from the rhizome extract, as well as from the leaves extract with the absence of 9. Three known steroid compounds, i.e., spinasterone (7), spinasterol (8), and 24-methylcholesta-7-en-3β-on (6), were further identified from the pseudostem extract. Molecular docking showed that steroids compounds 7, 8, and 6 have lower predictive binding energies (MMGBSA) than other metabolites with binding energy of -87.91, -78.11, and -68.80 kcal/mole, respectively. Further characterization on the single isolated compound by NMR showed that 6 was identified and possessed 75% inhibitory activity on SARS-CoV-2 3CL protease enzyme that was slightly different with the positive control GC376 (77%). MD simulations showed the complex stability with compound 6 during 100 ns simulation time.Entities:
Keywords: 24-Methylcholesta-7-en-3β-on; 3CL Protease; LC-MS/MS; SARS-CoV-2; Steroids; Zingiber officinale
Mesh:
Substances:
Year: 2021 PMID: 34500664 PMCID: PMC8434146 DOI: 10.3390/molecules26175230
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Diversity of secondary metabolites on Z. officinale methanol extract identified by GC-MS.
Compounds identified by LC-MS/MS from the isolate of Z. officinale n-hexane extract.
| Compound’s Code | Compounds Identified | Rt (min) | [M + H]+ | |
|---|---|---|---|---|
| Leaves |
| ( | 9.96 | 419.3156 |
|
| Isocyperol | 9.45 | 221.1910 | |
|
| 9.53 | 336.3268 | ||
|
| Nootkatone | 9.38 | 219.1752 | |
|
| Candidate mass C22H45NO | 10.04 | 340.3577 | |
| Pseudostems |
| 24-methylcholesta-7-en-3 | 10.25 | 399.3618 |
|
| Spinasterone | 10.29 | 411.3616 | |
|
| Spinasterol | 10.37 | 413.3770 | |
| Rhizomes |
| ( | 9.96 | 419.3156 |
|
| Isocyperol | 9.45 | 221.1910 | |
|
| 9.53 | 336.3268 | ||
|
| Nootkatone | 9.38 | 219.1752 | |
|
| 5-hydro-7,8,2′-trimethoxyflavanone | 9.25 | 329.1026 |
Docking molecular of identified metabolites on SARS-CoV-2 3CL protease with baicalein as the native ligand (pdb code 6m2n).
| Identified Compounds | Compound’s Code | MMGBSA Binding Energy (kcal/mol) |
|---|---|---|
| Spinasterone |
| −87.41 |
| Spinasterol |
| −78.11 |
| 24-methylcholesta-7-en-3 |
| −68.80 |
|
| −65.44 | |
| 5-hydro-7,8,2′-trimethoxyflavanone |
| −65.42 |
| ( |
| −65.26 |
| Isocyperol |
| −62.04 |
| Nootkatone |
| −53.24 |
| Baicalein | - | −47.14 |
| Indinavir | - | −76.44 |
| Remdesivir | - | −68.55 |
Figure 2Molecular interactions of SARS-CoV-2 3CL protease of 7 (A), 8 (B), 6 (C) dan baicalein (D) as co-crystallized inhibitor.
1H (500 MHz) and 13C NMR (150 MHz) spectral data of 6 (CDCl3).
| P. | δC ( | δH ( |
|---|---|---|
| 1 | 35.6 | 1.65–1.71 ( |
| 2 | 39.5 | 1.98–2.03 ( |
| 3 | 204.6 | - |
| 4 | 33.9 | 2.26–2.31 ( |
| 5 | 55.8 | 1.00–1.02 ( |
| 6 | 32.9 | 1.27–1.28 ( |
| 7 | 123.7 | 5.71 ( |
| 8 | 140.9 | - |
| 9 | 53.8 | 0.95 ( |
| 10 | 38.6 | - |
| 11 | 20.9 | 1.00–1.01 ( |
| 12 | 32.0 | 1.81–1.84 ( |
| 13 | 42.2 | - |
| 14 | 39.6 | 1.12 ( |
| 15 | 25.4 | 1.21 ( |
| 16 | 29.7 | 1.27 ( |
| 17 | 45.8 | 0.88 ( |
| 18 | 11.9 | 0.70 ( |
| 19 | 17.4 | 1.17 ( |
| 20 | 31.9 | 1.81–1.84 ( |
| 21 | 19.8 | 0.81–0.82 ( |
| 22 | 29.1 | 1.28 ( |
| 23 | 40.5 | 1.22 ( |
| 24 | 55.9 | 1.07 ( |
| 25 | 36.0 | 1.24 ( |
| 26 | 18.7 | 0.90–0.91 ( |
| 27 | 19.5 | 1.00–1.01 ( |
| 28 | 20.1 | 0.79–0.82 ( |
Figure 3Molecular structure of 24-methylcholesta-7-en-3β-on (A) and its H-H COSY and HMBC correlation (B).
Figure 4The % inhibition of 24-methylcholesta-7-en-3β-on (6) (200 µg/mL~500 µM) against SARS-CoV-2 3CLpro by in vitro assay. GC376 (100 µM) was used as the positive control and the experiment was triplicated.
Figure 5RMSD analysis of MD simulation trajectory (blue = RMSD of the Cα protein; red = RMSD of the ligand-bound protein). The RMSD plot obtained for 6 on SARS-CoV-2 3CL protease complex (PDB ID 6m2n).
Figure 6Molecular interaction (A), bonding type (B), and RMSF plot (C) of compound 6 with SARS-CoV-2 3CL protease after 100 ns MD simulation.